birt 2584 xx
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT02259894)
Timeline
Indications
Mechanism of action
ITGAL inhibitor
- Integrin beta-2INHIBITOR
ITGB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- birt 2584 xx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00333411 | Phase 2 | Jun 1, 2006 | Boehringer Ingelheim |
| NCT02256813 | Phase 1 | Sep 1, 2005 | Boehringer Ingelheim |
| NCT02256748 | Phase 1 | Jun 1, 2005 | Boehringer Ingelheim |
| NCT02256761 | Phase 1 | Jan 1, 2005 | Boehringer Ingelheim |
| NCT02256878 | Phase 1 | Aug 1, 2004 | Boehringer Ingelheim |
| NCT02259894 | Phase 1 | Mar 1, 2004 | Boehringer Ingelheim |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 6 | 6 | 2 | 2004 |
1 organizations
Page 1 / 1